Healthcare provider profile · identity verified

Misty Windom Polson, FNP-C

Nurse Practitioner · COLUMBIA, SC · NPI 1396286365

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	169	60
Levothyroxine Sodium	Levothyroxine Sodium	119	40
Amlodipine Besylate	Amlodipine Besylate	109	39
Rosuvastatin Calcium	Rosuvastatin Calcium	98	35
Pantoprazole Sodium	Pantoprazole Sodium	96	32
Alprazolam	Alprazolam	86	22
Lisinopril	Lisinopril	85	30
Tamsulosin Hcl	Tamsulosin Hcl	76	23
Mounjaro	Tirzepatide	63	11
Losartan Potassium	Losartan Potassium	61	22
Omeprazole	Omeprazole	59	19
Metformin Hcl	Metformin Hcl	57	26
Metoprolol Succinate	Metoprolol Succinate	54	22
Duloxetine Hcl	Duloxetine Hcl	51	15
Trazodone Hcl	Trazodone Hcl	47	14
Fluticasone Propionate	Fluticasone Propionate	42	23
Albuterol Sulfate Hfa	Albuterol Sulfate	41	17
Simvastatin	Simvastatin	39	14
Montelukast Sodium	Montelukast Sodium	38	15
Potassium Chloride	Potassium Chloride	37	14
Farxiga	Dapagliflozin Propanediol	36	suppressed
Bupropion Xl	Bupropion Hcl	35	14
Sertraline Hcl	Sertraline Hcl	35	suppressed
Tramadol Hcl	Tramadol Hcl	35	suppressed
Gabapentin	Gabapentin	34	11
Pravastatin Sodium	Pravastatin Sodium	34	11
Furosemide	Furosemide	33	14
Allopurinol	Allopurinol	29	11
Fluoxetine Hcl	Fluoxetine Hcl	29	suppressed
Diclofenac Sodium	Diclofenac Sodium	28	15
Metoprolol Tartrate	Metoprolol Tartrate	28	suppressed
Eliquis	Apixaban	27	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	27	12
Hydrochlorothiazide	Hydrochlorothiazide	27	suppressed
Metformin Hcl Er	Metformin Hcl	27	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	25	suppressed
Famotidine	Famotidine	25	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	25	11
Diazepam	Diazepam	24	suppressed
Rybelsus	Semaglutide	24	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	24	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	24	suppressed
Alendronate Sodium	Alendronate Sodium	23	suppressed
Celecoxib	Celecoxib	22	suppressed
Ondansetron Odt	Ondansetron	22	suppressed
Prednisone	Prednisone	22	13
Clonazepam	Clonazepam	21	suppressed
Ezetimibe	Ezetimibe	21	suppressed
Fluconazole	Fluconazole	21	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	20	14
Esomeprazole Magnesium	Esomeprazole Magnesium	20	suppressed
Meloxicam	Meloxicam	20	suppressed
Valsartan	Valsartan	20	suppressed
Lorazepam	Lorazepam	19	suppressed
Atenolol	Atenolol	18	suppressed
Donepezil Hcl	Donepezil Hcl	18	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	18	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	18	suppressed
Buspirone Hcl	Buspirone Hcl	17	suppressed
Citalopram Hbr	Citalopram Hydrobromide	17	suppressed
Eszopiclone	Eszopiclone	17	suppressed
Clopidogrel	Clopidogrel Bisulfate	16	suppressed
Ozempic	Semaglutide	16	suppressed
Carvedilol	Carvedilol	15	suppressed
Chlorthalidone	Chlorthalidone	15	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	15	suppressed
Trulicity	Dulaglutide	15	suppressed
Valacyclovir	Valacyclovir Hcl	15	suppressed
Jardiance	Empagliflozin	14	suppressed
Pristiq	Desvenlafaxine Succinate	14	suppressed
Benazepril Hcl	Benazepril Hcl	13	suppressed
Bupropion Hcl Sr	Bupropion Hcl	13	suppressed
Glipizide Er	Glipizide	13	suppressed
Ketoconazole	Ketoconazole	13	suppressed
Levemir Flexpen	Insulin Detemir	13	suppressed
Olmesartan Medoxomil	Olmesartan Medoxomil	13	suppressed
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	13	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	13	suppressed
Fenofibrate	Fenofibrate	11	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	11	suppressed
Linzess	Linaclotide	11	suppressed
Paroxetine Hcl	Paroxetine Hcl	11	suppressed
Risedronate Sodium	Risedronate Sodium	11	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	11	suppressed
Xarelto	Rivaroxaban	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error